

# John Dickson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3254186/publications.pdf>

Version: 2024-02-01

89  
papers

6,230  
citations

126858

33  
h-index

71651

76  
g-index

92  
all docs

92  
docs citations

92  
times ranked

8837  
citing authors

#	ARTICLE	IF	CITATIONS
1	The effect of modern PET technology and techniques on the EANM paediatric dosage card. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1964-1969.	3.3	7
2	Utility of 18F-fluorodeoxyglucose positron emission tomography in presurgical evaluation of patients with epilepsy: A multicenter study. <i>Epilepsia</i> , 2022, 63, 1238-1252.	2.6	18
3	Associations of $\beta$ -Amyloid and Vascular Burden With Rates of Neurodegeneration in Cognitively Normal Members of the 1946 British Birth Cohort. <i>Neurology</i> , 2022, 99, .	1.5	12
4	Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The $\beta$ -Exenatide-PD3 study. <i>BMJ Open</i> , 2021, 11, e047993.	0.8	32
5	OUP accepted manuscript. <i>Brain</i> , 2021, 144, 434-449.	3.7	54
6	Absolute Quantification in Diagnostic SPECT/CT: The Phantom Premise. <i>Diagnostics</i> , 2021, 11, 2333.	1.3	7
7	Vascular risk factors and amyloid pathology: Additive or interactive associations?. <i>Alzheimer's and Dementia</i> , 2020, 16, e037922.	0.4	0
8	EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1885-1912.	3.3	134
9	What scans we will read: imaging instrumentation trends in clinical oncology. <i>Cancer Imaging</i> , 2020, 20, 38.	1.2	35
10	Metabolic lesion-deficit mapping of human cognition. <i>Brain</i> , 2020, 143, 877-890.	3.7	13
11	Lung delivery of MSCs expressing anti-cancer protein TRAIL visualised with 89Zr-oxine PET-CT. <i>Stem Cell Research and Therapy</i> , 2020, 11, 256.	2.4	32
12	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1189-1201.	1.2	38
13	Hybrid Imaging in conventional nuclear medicine. , 2020, , .		0
14	Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. <i>Lancet Neurology</i> , The, 2019, 18, 942-952.	4.9	178
15	Quantitative SPECT: the time is now. <i>EJNMMI Physics</i> , 2019, 6, 4.	1.3	56
16	Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 382-387.	1.8	34
17	Does quantification have a role to play in the future of bone SPECT?. <i>European Journal of Hybrid Imaging</i> , 2019, 3, 8.	0.6	11
18	Underestimation of 68Ga PET/CT SUV caused by activity overestimation using default calibrator settings. <i>Physica Medica</i> , 2019, 59, 158-162.	0.4	7

#	ARTICLE	IF	CITATIONS
19	Quantitative SPECT. Nuclear Medicine Communications, 2019, 40, 986-994.	0.5	9
20	Dopamine reuptake transporterâ€“singleâ€“photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease. Movement Disorders, 2018, 33, 478-482.	2.2	25
21	The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [123I]FP-CIT SPECT imaging. EJNMMI Research, 2017, 7, 10.	1.1	16
22	Simultaneous 68Ga DOTATATE Positron Emission Tomography/Magnetic Resonance Imaging in Meningioma Target Contouring: Feasibility and Impact Upon Interobserver Variability Versus Positron Emission Tomography/Computed Tomography and Computed Tomography/Magnetic Resonance Imaging. Clinical Oncology, 2017, 29, 448-458.	0.6	10
23	Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 1664-1675.	6.3	527
24	[ICâ€“Pâ€“004]: A COMPARISON OF TECHNIQUES FOR QUANTIFYING AMYLOID BURDEN ON A COMBINED PET/MR SCANNER. Alzheimer's and Dementia, 2017, 13, P12.	0.4	0
25	Study protocol: Insight 46 â€“ a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurology, 2017, 17, 75.	0.8	64
26	[123I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. EJNMMI Physics, 2017, 4, 8.	1.3	46
27	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2017, 14, 169-186.	12.5	792
28	[P3â€“348]: EXPLORING THE POPULATION PREVALENCE OF Î²â€“AMYLOID BURDEN: AN ANALYSIS OF 250 INDIVIDUALS BORN IN MAINLAND BRITAIN IN THE SAME WEEK IN 1946. Alzheimer's and Dementia, 2017, 13, P1088.	0.4	0
29	[P3â€“373]: A COMPARISON OF TECHNIQUES FOR QUANTIFYING AMYLOID BURDEN ON A COMBINED PET/MR SCANNER. Alzheimer's and Dementia, 2017, 13, P1100.	0.4	0
30	Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?. Journal of Alzheimer's Disease, 2016, 54, 1297-1302.	1.2	21
31	<sup>18</sup>F-FECH PET/CT to Assess Clinically Significant Disease in Prostate Cancer: Correlation With Maximum and Total Cancer Core Length Obtained via MRI-Guided Template Mapping Biopsies. American Journal of Roentgenology, 2016, 207, 1297-1306.	1.0	1
32	A novel use of arterial spin labelling MRI to demonstrate focal hypoperfusion in individuals with posterior cortical atrophy: a multimodal imaging study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1032-1034.	0.9	9
33	Comparison of rubidium-82 myocardial blood flow quantification with coronary calcium score for evaluation of coronary artery stenosis. Nuclear Medicine Communications, 2016, 37, 197-206.	0.5	5
34	Reduction in camera-specific variability in [123I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1323-1336.	3.3	35
35	Implementation of the European multicentre database of healthy controls for [123I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1315-1322.	3.3	29
36	MR Imagingâ€“Guided Partial Volume Correction of PET Data in PET/MR Imaging. PET Clinics, 2016, 11, 161-177.	1.5	32

#	ARTICLE	IF	CITATIONS
37	Simultaneous PET-MRI Studies of the Concordance of Atrophy and Hypometabolism in Syndromic Variants of Alzheimer's Disease and Frontotemporal Dementia: An Extended Case Series. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 639-653.	1.2	15
38	Establishment of an open database of realistic simulated data for evaluation of partial volume correction techniques in brain PET/MR. <i>EJNMMI Physics</i> , 2015, 2, A44.	1.3	1
39	Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 440-446.	1.2	16
40	Multi-contrast attenuation map synthesis for PET/MR scanners: assessment on FDG and Florbetapir PET tracers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1447-1458.	3.3	35
41	USING FLORBETAPIR PET TO INCREASE DIAGNOSTIC CERTAINTY IN ATYPICAL DEMENTIAS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, e4.112-e4.	0.9	0
42	A comparison of CT- and MR-based attenuation correction in neurological PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1176-1189.	3.3	70
43	Quantification of Myocardial Blood Flow in Absolute Terms Using 82Rb PET Imaging. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 1119-1127.	2.3	144
44	The utility of 18F-fluorodeoxyglucose PET (FDG PET) in epilepsy surgery. <i>Epilepsy Research</i> , 2014, 108, 1306-1314.	0.8	94
45	Attenuation Correction Synthesis for Hybrid PET-MR Scanners: Application to Brain Studies. <i>IEEE Transactions on Medical Imaging</i> , 2014, 33, 2332-2341.	5.4	311
46	Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1938-1946.	3.3	60
47	Association of central serotonin transporter availability and body mass index in healthy Europeans. <i>European Neuropsychopharmacology</i> , 2014, 24, 1240-1247.	0.3	34
48	Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2014, 4, 337-344.	1.5	206
49	P1-286: STRATIFICATION OF DEMENTIA SUB-TYPES USING ARTERIAL SPIN LABELED MRI. , 2014, 10, P414-P415.		1
50	Effect of scatter correction when comparing attenuation maps: Application to brain PET/MR. , 2014, , .		10
51	No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [123I]FP-CIT (DaTSCAN) and SPECT. <i>EJNMMI Research</i> , 2013, 3, 39.	1.1	21
52	European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 213-227.	3.3	198
53	Patients with rest-tremor and scans with ipsilateral dopaminergic deficit. <i>Journal of Neurology</i> , 2013, 260, 1132-1135.	1.8	10
54	Simultaneous PET/MRI in frontotemporal dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 468-469.	3.3	9

#	ARTICLE	IF	CITATIONS
55	Value of Semiquantitative Analysis for Clinical Reporting of 123I-2- $\beta$ -Carbomethoxy-3 $\beta$ -(4-Iodophenyl)-N-(3-Fluoropropyl)Nortropane SPECT Studies. <i>Journal of Nuclear Medicine</i> , 2013, 54, 714-722.	2.8	62
56	No association between striatal dopamine transporter binding and body mass index: A multi-center European study in healthy volunteers. <i>NeuroImage</i> , 2013, 64, 61-67.	2.1	47
57	Clinical evaluation of reducing acquisition time on single-photon emission computed tomography image quality using proprietary resolution recovery software. <i>Nuclear Medicine Communications</i> , 2013, 34, 1116-1123.	0.5	20
58	18F-DOPA PET and enhanced CT imaging for congenital hyperinsulinism. <i>Nuclear Medicine Communications</i> , 2013, 34, 601-608.	0.5	34
59	Attenuation Correction Synthesis for Hybrid PET-MR Scanners. <i>Lecture Notes in Computer Science</i> , 2013, 16, 147-154.	1.0	31
60	Exenatide and the treatment of patients with Parkinson's disease. <i>Journal of Clinical Investigation</i> , 2013, 123, 2730-2736.	3.9	361
61	Novel Positron Emission Tomography/Computed Tomography of Diffuse Parenchymal Lung Disease Combining a Labeled Somatostatin Receptor Analogue and 2-Deoxy-2 [ <sup>18</sup> F] Fluoro-D-Glucose. <i>Molecular Imaging</i> , 2012, 11, 7290.2011.00030.	0.7	19
62	Diagnostic accuracy of 123I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: A meta-analysis of published studies. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 225-229.	1.1	91
63	Is transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson's disease?. <i>Movement Disorders</i> , 2012, 27, 1182-1185.	2.2	32
64	Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 188-197.	3.3	48
65	Partial volume correction in SPECT reconstruction with OSEM. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2011, 648, S85-S88.	0.7	18
66	Calibration of gamma camera systems for a multicentre European 123I-FP-CIT SPECT normal database. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1529-1540.	3.3	73
67	PET imaging for prediction of response to therapy and outcome in oesophageal carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1591-1594.	3.3	7
68	Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 6021-6028.	3.2	123
69	Does intravenous $\delta^9$ -tetrahydrocannabinol increase dopamine release? A SPET study. <i>Journal of Psychopharmacology</i> , 2011, 25, 1462-1468.	2.0	84
70	101 poster: Techniques to Delineate Hypoxic BTV Using 64Cu-ATSM in Squamous Cell Carcinoma of the Head and Neck. <i>Radiotherapy and Oncology</i> , 2010, 94, S39-S40.	0.3	0
71	86 poster: Advantages of Fixed and Adaptive 18FDG PET/CT Based BTV Delineation in Squamous Cell Carcinoma of the Head and Neck : Effect on Dose Escalated IMRT.. <i>Radiotherapy and Oncology</i> , 2010, 94, S33-S34.	0.3	0
72	The impact of reconstruction method on the quantification of DaTSCAN images. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 23-35.	3.3	67

#	ARTICLE	IF	CITATIONS
73	Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: A clinical and electrophysiological study. <i>Movement Disorders</i> , 2010, 25, 560-569.	2.2	223
74	Nonlaxative PET/CT Colonography: Feasibility, Acceptability, and Pilot Performance in Patients at Higher Risk of Colonic Neoplasia. <i>Journal of Nuclear Medicine</i> , 2010, 51, 854-861.	2.8	27
75	Evaluation of an OSEM-based PVC method for SPECT with clinical data. , 2010, , .		2
76	A Comparison of <sup>68</sup> Ga-DOTATATE and <sup>18</sup> F-FDG PET/CT in Pulmonary Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1927-1932.	2.8	228
77	Vascular Inflammation Imaging with <sup>18</sup> F-FDG PET/CT: When to Image?. <i>Journal of Nuclear Medicine</i> , 2009, 50, 854-857.	2.8	59
78	Idiopathic Pulmonary Fibrosis and Diffuse Parenchymal Lung Disease: Implications from Initial Experience with <sup>18</sup> F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2009, 50, 538-545.	2.8	138
79	Evidence for pre and postsynaptic nigrostriatal dysfunction in the fragile X tremor-Ataxia syndrome. <i>Movement Disorders</i> , 2009, 24, 1245-1247.	2.2	15
80	Assessment of left ventricular function at rest using rubidium-82 myocardial perfusion PET: comparison of four software algorithms with simultaneous 64-slice coronary CT angiography. <i>Nuclear Medicine Communications</i> , 2009, 30, 918-925.	0.5	7
81	Functional imaging of neuroendocrine tumors with combined PET/CT using <sup>68</sup> Ga-DOTATATE (DOTA-D-Phe <sup>1</sup> , Tyr <sup>3</sup> -octreotate) and <sup>18</sup> F-FDG. <i>Cancer</i> , 2008, 112, 2447-2455.	2.0	431
82	CT coronary angiography: Quantitative assessment of myocardial perfusion using test bolus data—initial experience. <i>European Radiology</i> , 2008, 18, 2155-2163.	2.3	20
83	Evaluation of a low-dose/slow-rotating SPECT-CT system. <i>Physics in Medicine and Biology</i> , 2008, 53, 2495-2508.	1.6	34
84	Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). <i>Movement Disorders</i> , 2007, 22, 2210-2215.	2.2	304
85	Cardiac <sup>82</sup> rubidium PET/CT: initial European experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1965-1972.	3.3	21
86	Detection and validation of the body edge in low count emission tomography images. <i>Computer Methods and Programs in Biomedicine</i> , 2006, 84, 153-161.	2.6	14
87	Oral contrast medium in PET/CT: should you or shouldn't you?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 1160-1166.	3.3	39
88	Prediction of clinical outcome in treated neuroendocrine tumours of carcinoid type using functional volumes on <sup>111</sup> In-pentetreotide SPECT imaging. <i>Nuclear Medicine Communications</i> , 2004, 25, 253-257.	0.5	21
89	An assessment of perfusion deficits in decompression illness using <sup>99</sup> Tc <sup>m</sup> HMPAO SPET and statistical parametric mapping. <i>Nuclear Medicine Communications</i> , 2001, 22, 423-428.	0.5	3